Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

Migraine, epilepsy and genetics: an interview with Dr. Melodie Winawer

This work is the product of an extraordinary consortium called the Epilepsy Phenome/Genome project (EPGP). It is a consortium of 27 centres in the U.S. and internationally with several hundred physicians and staff who have worked together to enrol more than 4000 patients with epilepsy and their family members.

7 Feb 2013

Fish-related ciguatoxin danger highlighted

Researchers report that 28 cases of ciguatera fish poisoning occurred in New York City during 2010–2011, a greater number than were reported during the preceding 10-year period.

6 Feb 2013

Teva initiates enrollment in AZILECT Phase IV clinical study for PD-MCI

Teva Pharmaceutical Industries Ltd. announced today enrollment of the first patient in the MODERATO study - a Phase IV clinical study designed to evaluate the effect of AZILECT (rasagiline tablets) on cognitive function in adults with mild cognitive impairment (MCI) in Parkinson's disease (PD-MCI).

6 Feb 2013

Orphan, St George's sign licensing agreement to develop new therapies for metabolic disorders

St George's, University of London has signed an exclusive worldwide licensing agreement with rare-disease research-and-development firm Orphan Technologies Ltd to develop new therapies for deadly metabolic disorders.

5 Feb 2013

Topline results from Gilead’s FISSION and NEUTRINO Phase 3 studies on HCV infection

Gilead Sciences today announced topline results from two Phase 3 studies, FISSION and NEUTRINO, evaluating a 12-week course of the once-daily nucleotide sofosbuvir in combination with ribavirin (FISSION) and in combination with ribavirin and pegylated interferon (NEUTRINO) among treatment-naïve patients with chronic hepatitis C virus (HCV) infection.

5 Feb 2013

Oral toxicity is frequent limitation of mTOR therapy

Oral mucositis is a frequent complication in patients taking mTOR inhibitors and a major reason for dose reductions and discontinuations in clinical trials, according to a review of this class of cancer drugs.

4 Feb 2013

Women still underestimate the seriousness of heart disease

Although heart disease remains the No. 1 killer nationally for women-—responsible for one out of every three deaths—-many of today's women still underestimate the seriousness of the disease and their risks, says Liliana Cohen, MD, a board-certified cardiologist with The Robert Wood Johnson Medical Group.

4 Feb 2013

Study supports hypothesis that disulfiram reduces drug consumption by blocking DβH

Disulfiram was the first medication approved for the treatment of alcoholism over 50 years ago. It works, at least in part, by preventing the metabolism of an alcohol by-product, acetaldehyde. High levels of acetaldehyde in the body quickly cause unpleasant symptoms, including nausea, vomiting, headache, and accelerated heart rate. Thus, disulfiram provides a very strong incentive to avoid drinking.

1 Feb 2013

Delaware District Court rules in favor of Pfizer in RAPAMUNE patent case

Pfizer Inc. said today that the United States District Court for the District of Delaware ruled that Pfizer's patent covering a method for using sirolimus, the active ingredient in RAPAMUNE®, for the inhibition of organ transplant rejection is valid and infringed.

31 Jan 2013

Bispectral index benefits for postoperative recovery unclear

A secondary analysis of two large clinical trials fails to settle the question of whether use of the bispectral index rather than end-tidal anesthetic concentration to monitor general anesthesia results in faster patient recovery.

31 Jan 2013

FDA approves Genzyme’s KYNAMRO to treat homozygous familial hypercholesterolemia

Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for KYNAMROTM (mipomersen sodium) injection.

30 Jan 2013

Genzyme receives FDA approval for Kynamro to treat homozygous familial hypercholesterolemia

The U.S. Food and Drug Administration today approved Kynamro (mipomersen sodium) injection as an addition to lipid-lowering medications and diet to treat patients with a rare type of high cholesterol called homozygous familial hypercholesterolemia (HoFH).

30 Jan 2013

Sanofi announces availability of Auvi-Q in U.S. retail pharmacies

Sanofi announced today that Auvi-Q (epinephrine injection, USP) is now available in U.S. retail pharmacies nationwide with a prescription from a healthcare provider.

29 Jan 2013

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.

28 Jan 2013

FDA accepts Genzyme’s LEMTRADA sBLA for review

Genzyme, a Sanofi Company, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental Biologics License Application (sBLA) file seeking approval of LEMTRADA (alemtuzumab) for the treatment of relapsing multiple sclerosis (RMS).

28 Jan 2013

Interim results from Seattle Genetics’ ASG-5ME phase I trial on metastatic PDA

Seattle Genetics, Inc. today presented interim results from a phase I clinical trial evaluating ASG-5ME for the treatment of metastatic pancreatic ductal adenocarcinoma (PDA) at the American Society of Clinical Oncology (ASCO) 2013 Gastrointestinal Cancers Symposium being held January 24-26, 2013 in San Francisco, CA.

28 Jan 2013

Genentech receives FDA approval for new use of Avastin plus chemotherapy to treat mCRC

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved a new use of Avastin (bevacizumab) in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy for people with metastatic colorectal cancer (mCRC).

23 Jan 2013

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

Australian biopharmaceutical company Specialised Therapeutics Australia announces that a phase III clinical trial of world leading breast cancer drug ABRAXANE (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved survival times, with double the number of patients surviving two years.

23 Jan 2013

EMA adopts positive opinion for Pfizer’s bosutinib conditional approval in the EU

Pfizer Inc. announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion regarding the conditional marketing authorization of bosutinib in the European Union for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitor(s) (TKIs) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.

19 Jan 2013

Mass poultry vaccination programmes lead to dramatic decline in Salmonella infections

Mass poultry vaccination programmes introduced to combat Salmonella infections have led to a dramatic fall in the number of cases since the late 1990s, according to a researcher at the University of Liverpool.

17 Jan 2013

Nausea News and Research

Further Reading

Migraine, epilepsy and genetics: an interview with Dr. Melodie Winawer

Fish-related ciguatoxin danger highlighted

Teva initiates enrollment in AZILECT Phase IV clinical study for PD-MCI

Orphan, St George's sign licensing agreement to develop new therapies for metabolic disorders

Topline results from Gilead’s FISSION and NEUTRINO Phase 3 studies on HCV infection

Oral toxicity is frequent limitation of mTOR therapy

Women still underestimate the seriousness of heart disease

Study supports hypothesis that disulfiram reduces drug consumption by blocking DβH

Delaware District Court rules in favor of Pfizer in RAPAMUNE patent case

Bispectral index benefits for postoperative recovery unclear

FDA approves Genzyme’s KYNAMRO to treat homozygous familial hypercholesterolemia

Genzyme receives FDA approval for Kynamro to treat homozygous familial hypercholesterolemia

Sanofi announces availability of Auvi-Q in U.S. retail pharmacies

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

FDA accepts Genzyme’s LEMTRADA sBLA for review

Interim results from Seattle Genetics’ ASG-5ME phase I trial on metastatic PDA

Genentech receives FDA approval for new use of Avastin plus chemotherapy to treat mCRC

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

EMA adopts positive opinion for Pfizer’s bosutinib conditional approval in the EU

Mass poultry vaccination programmes lead to dramatic decline in Salmonella infections

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News